摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-[5-[4-[4-(4-methylcyclohexyl)-1-piperazinyl]phenyl]-1,3,4-thiadiazol-2-yl]benzoyloxy]-1H-1,2,3-benzotriazole | 355379-97-4

中文名称
——
中文别名
——
英文名称
1-[4-[5-[4-[4-(4-methylcyclohexyl)-1-piperazinyl]phenyl]-1,3,4-thiadiazol-2-yl]benzoyloxy]-1H-1,2,3-benzotriazole
英文别名
benzotriazol-1-yl 4-[5-[4-[4-(4-methylcyclohexyl)piperazin-1-yl]phenyl]-1,3,4-thiadiazol-2-yl]benzoate
1-[4-[5-[4-[4-(4-methylcyclohexyl)-1-piperazinyl]phenyl]-1,3,4-thiadiazol-2-yl]benzoyloxy]-1H-1,2,3-benzotriazole化学式
CAS
355379-97-4
化学式
C32H33N7O2S
mdl
——
分子量
579.726
InChiKey
VEMICEJSJOFHEI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.7
  • 重原子数:
    42
  • 可旋转键数:
    7
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.34
  • 拓扑面积:
    118
  • 氢给体数:
    0
  • 氢受体数:
    9

反应信息

  • 作为反应物:
    描述:
    1-[4-[5-[4-[4-(4-methylcyclohexyl)-1-piperazinyl]phenyl]-1,3,4-thiadiazol-2-yl]benzoyloxy]-1H-1,2,3-benzotriazole二甲羟胺盐酸盐N,N-二异丙基乙胺 作用下, 以 DMF (N,N-dimethyl-formamide) 为溶剂, 反应 4.0h, 生成 N-methoxy-N-methyl-4-[5-[4-[4-(cis-4-methylcyclohexyl)-1-piperazinyl]phenyl]-1,3,4-thiadiazol-2-yl]benzamide
    参考文献:
    名称:
    New compound
    摘要:
    本发明涉及一种由以下一般式(I)表示的新脂肽化合物:其中R1、R2、R3、R4和R5如描述中所定义,或其盐,具有抗微生物活性(特别是抗真菌活性),对β-1,3-葡聚糖合酶的抑制活性,制备过程,包含该化合物的药物组合物,以及预防和/或治疗包括肺孢子虫感染(例如肺孢子虫性肺炎)在人类或动物中的传染病的方法。
    公开号:
    US20050004014A1
点击查看最新优质反应信息

文献信息

  • Cyclic hexapeptide derivatives
    申请人:——
    公开号:US20030083238A1
    公开(公告)日:2003-05-01
    This invention relates to new polypeptide compound represented by the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on &bgr;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystic carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
    本发明涉及一种由普通式(I)所表示的新的多肽化合物,其中R1、R2、R3、R4、R5和R6如说明书中所定义,或其盐,具有抗微生物活性(特别是抗真菌活性),对β-1,3-葡聚糖合酶的抑制活性,以及其制备方法、包含其的药物组合物,以及预防和/或治疗人类或动物的传染病(包括肺孢子虫感染,例如肺孢子虫肺炎)的方法。
  • Echinocandin cyclic peptide derivatives
    申请人:Mizuno Hiroaki
    公开号:US20050181988A1
    公开(公告)日:2005-08-18
    This invention relates to new lipopeptide compound represented by the following general formula (I) wherein R 1 , R 2 , R 3 , R4 and R 5 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or thereapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal. In particular, R 4 is an alkyl moiety which is substituted with an eventually protected and/or further substituted selected from amino, carboxy, guanidino, heterocyclic-carbonyl, alkyl-carbamoyl.
    本发明涉及一种新的脂肽化合物,其通式如下(I),其中R1、R2、R3、R4和R5如描述中所定义,或其盐具有抗微生物活性(特别是抗真菌活性),对β-1,3-葡聚糖合酶的抑制活性,制备方法,包括它的药物组合物,以及预防和/或治疗包括肺孢子虫感染(例如肺孢子虫肺炎)在人类或动物中的传染病的方法。特别地,R4是一种烷基基团,其被基、羧基、鸟氨酸、杂环羰基、烷基基酰等保护和/或进一步取代。
  • CYCLIC HEXAPEPTIDE DERIVATIVES
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP1259535A1
    公开(公告)日:2002-11-27
  • US6884774B2
    申请人:——
    公开号:US6884774B2
    公开(公告)日:2005-04-26
  • [EN] CYCLIC HEXAPEPTIDE DERIVATIVES<br/>[FR] DERIVES CYCLIQUES D'HEXAPEPTIDES
    申请人:FUJISAWA PHARMACEUTICAL CO
    公开号:WO2001060846A1
    公开(公告)日:2001-08-23
    This invention relates to new polypeptide compound represented by the general formula (I) wherein R?1, R2, R3, R4, R5 and R6¿ are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystic carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
查看更多